With the increasing population, the incidence rates of various chronic diseases, such as diabetes, autoimmune disorders, cardiovascular disorders and oncological disorders, are witnessing an upward trend.
The global prefilled syringes market size is estimated to grow from USD 3.02 billion in 2024 to USD 4.97 billion by 2035, representing a CAGR of 4.6% during the forecast period till 2035.
Most of the prefilled syringes are being developed with luer needle system; these syringes have threaded rims provides a unique locking system, thereby, preventing the needle from being pulled off by the syringe body inadvertently. Further, prefilled syringes are developed in different volume formats, considering the preferences and needs of the customers.
In pursuit of building a competitive edge, stakeholders are actively upgrading their existing capabilities to enhance their product portfolios and comply with the evolving industry benchmarks. In order to determine the relative competitiveness of prefilled syringes, we focused on several relevant parameters, such as manufacturer strength (in terms of experience and company size), product portfolio strength (in terms of current status of development, number of chambers and volume of syringe available) and type of needle system (luer lock, luer cone and staked needle). SCHOTT TopPac (manufactured by SCHOTT Pharma) emerged as the most competent prefilled syringe, in terms of product portfolio strength, followed by Gx RTF ClearJect Needle Syringe (manufactured by Gerresheimer), available in staked needle format is produced in the company’s facility located in Pfreimd, Germany.
In terms of manufacturer strength, Pfizer (very large US-based firm) emerged as the leading player in this domain, having an experience of close to 175 years; the Abboject Syringe manufactured by the firm is a ready-to-use, prefilled emergency syringe for needle-free or shrouded-needle access.
Innovative pairing: prefilled syringe combination products shaping healthcare. It was identified over 120 drugs that have received approval to be used in combination with prefilled syringes, during the period 2013-2023 (till October) and over 50 drugs that are currently being developed in combination with prefilled syringes.
Majority of the drugs being evaluated in late stages of development (phase I/II or phase III) are targeting autoimmune disorders. It is worth mentioning that subcutaneous route is the most preferred route for drug administration by these combination products due to reduced pain and discomfort, convenient self-administration and stable drug absorption.
Prefilled syringes redefined: a look into the recent industry advancements. Expansions emerged as the most prominent type of initiative undertaken by stakeholders engaged in this domain; most of the expansion initiatives undertaken by prefilled syringe manufacturers within this domain were facility expansions and capacity expansions.
Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Prefilled Syringes Market.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To get sample report visit@
https://www.rootsanalysis.com/reports/prefilled-syringes-market/request-sample.html